ES2322172T3 - Composiciones que comprenden agentes desmetilantes como potenciadores de la inmunoterapia para el tratamiento de infecciones cronicas y enfermedades neoplasicas y metodos para tratar las mismas. - Google Patents

Composiciones que comprenden agentes desmetilantes como potenciadores de la inmunoterapia para el tratamiento de infecciones cronicas y enfermedades neoplasicas y metodos para tratar las mismas. Download PDF

Info

Publication number: ES2322172T3
Authority: ES; Spain
Prior art keywords: antigen; azacitidine; virus; group; specific
Prior art date: 2004-05-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES05750379T

Other languages

English (en)

Spanish (es)

Inventor

Jean-Marie Andrieu

Louis Wei-Lu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Biovaxim Ltd

Original Assignee

Biovaxim Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-26

Filing date

2005-05-26

Publication date

2009-06-17

2005-05-26 Application filed by Biovaxim Ltd filed Critical Biovaxim Ltd

2009-06-17 Application granted granted Critical

2009-06-17 Publication of ES2322172T3 publication Critical patent/ES2322172T3/es

2025-05-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 11
201000010099 disease Diseases 0.000 title claims abstract description 10
239000000203 mixture Substances 0.000 title claims description 35
238000000034 method Methods 0.000 title description 9
238000009169 immunotherapy Methods 0.000 title description 4
208000037581 Persistent Infection Diseases 0.000 title description 3
239000000427 antigen Substances 0.000 claims abstract description 98
108091007433 antigens Proteins 0.000 claims abstract description 98
102000036639 antigens Human genes 0.000 claims abstract description 98
241000700605 Viruses Species 0.000 claims abstract description 32
206010057248 Cell death Diseases 0.000 claims abstract description 30
230000009089 cytolysis Effects 0.000 claims abstract description 30
239000012649 demethylating agent Substances 0.000 claims abstract description 29
230000003612 virological effect Effects 0.000 claims abstract description 27
238000001727 in vivo Methods 0.000 claims abstract description 26
239000003814 drug Substances 0.000 claims abstract description 21
230000036039 immunity Effects 0.000 claims abstract description 7
230000001684 chronic effect Effects 0.000 claims abstract description 5
230000000840 anti-viral effect Effects 0.000 claims abstract description 4
238000004519 manufacturing process Methods 0.000 claims abstract description 4
230000002265 prevention Effects 0.000 claims abstract description 3
210000004027 cell Anatomy 0.000 claims description 34
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 28
108090000765 processed proteins & peptides Proteins 0.000 claims description 27
239000002671 adjuvant Substances 0.000 claims description 24
102000004196 processed proteins & peptides Human genes 0.000 claims description 20
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 18
230000001939 inductive effect Effects 0.000 claims description 16
229920001184 polypeptide Polymers 0.000 claims description 15
150000004676 glycans Chemical class 0.000 claims description 12
230000028993 immune response Effects 0.000 claims description 12
229920001282 polysaccharide Polymers 0.000 claims description 12
239000005017 polysaccharide Substances 0.000 claims description 12
239000003697 methyltransferase inhibitor Substances 0.000 claims description 8
230000036963 noncompetitive effect Effects 0.000 claims description 8
150000002632 lipids Chemical class 0.000 claims description 7
XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 6
229940123379 Methyltransferase inhibitor Drugs 0.000 claims description 6
230000001335 demethylating effect Effects 0.000 claims description 6
HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 claims description 5
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 5
229960004919 procaine Drugs 0.000 claims description 5
229930186217 Glycolipid Natural products 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
239000000284 extract Substances 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
239000000562 conjugate Substances 0.000 claims description 2
150000004677 hydrates Chemical class 0.000 claims description 2
230000004044 response Effects 0.000 claims description 2
150000001720 carbohydrates Chemical class 0.000 claims 2
235000014633 carbohydrates Nutrition 0.000 claims 2
101710135378 pH 6 antigen Proteins 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 description 30
230000014509 gene expression Effects 0.000 description 22
108090000623 proteins and genes Proteins 0.000 description 21
150000007523 nucleic acids Chemical class 0.000 description 20
241000725303 Human immunodeficiency virus Species 0.000 description 19
241001465754 Metazoa Species 0.000 description 19
239000003795 chemical substances by application Substances 0.000 description 16
108020004707 nucleic acids Proteins 0.000 description 16
102000039446 nucleic acids Human genes 0.000 description 16
241000699670 Mus sp. Species 0.000 description 15
201000011510 cancer Diseases 0.000 description 12
239000013612 plasmid Substances 0.000 description 12
108020004414 DNA Proteins 0.000 description 10
241000282414 Homo sapiens Species 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
239000013598 vector Substances 0.000 description 10
210000004443 dendritic cell Anatomy 0.000 description 9
230000000890 antigenic effect Effects 0.000 description 8
239000000839 emulsion Substances 0.000 description 8
244000005700 microbiome Species 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
241001430294 unidentified retrovirus Species 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
241000894006 Bacteria Species 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
210000000987 immune system Anatomy 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
210000004988 splenocyte Anatomy 0.000 description 7
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
241000701022 Cytomegalovirus Species 0.000 description 5
102000016397 Methyltransferase Human genes 0.000 description 5
108060004795 Methyltransferase Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
229940079593 drug Drugs 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000000813 microbial effect Effects 0.000 description 5
239000002245 particle Substances 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
241000702421 Dependoparvovirus Species 0.000 description 4
241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
241000194017 Streptococcus Species 0.000 description 4
238000003556 assay Methods 0.000 description 4
231100000433 cytotoxic Toxicity 0.000 description 4
230000001472 cytotoxic effect Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
230000006870 function Effects 0.000 description 4
230000003308 immunostimulating effect Effects 0.000 description 4
230000006872 improvement Effects 0.000 description 4
230000002458 infectious effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000011987 methylation Effects 0.000 description 4
238000007069 methylation reaction Methods 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
238000013519 translation Methods 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
230000007067 DNA methylation Effects 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
241001631646 Papillomaviridae Species 0.000 description 3
206010039491 Sarcoma Diseases 0.000 description 3
241000700584 Simplexvirus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000654 additive Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
-1 glucosamine disaccharide Chemical class 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
239000007764 o/w emulsion Substances 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
241000894007 species Species 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000010361 transduction Methods 0.000 description 3
230000026683 transduction Effects 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
108010077544 Chromatin Proteins 0.000 description 2
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108010041986 DNA Vaccines Proteins 0.000 description 2
229940021995 DNA vaccine Drugs 0.000 description 2
241000709661 Enterovirus Species 0.000 description 2
241000991587 Enterovirus C Species 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
241000222722 Leishmania <genus> Species 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
102000002508 Peptide Elongation Factors Human genes 0.000 description 2
108010068204 Peptide Elongation Factors Proteins 0.000 description 2
241001505332 Polyomavirus sp. Species 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
108091092356 cellular DNA Proteins 0.000 description 2
210000003483 chromatin Anatomy 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000007608 epigenetic mechanism Effects 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000000693 micelle Substances 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
238000012737 microarray-based gene expression Methods 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
238000012243 multiplex automated genomic engineering Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
244000045947 parasite Species 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
229930182490 saponin Natural products 0.000 description 2
150000007949 saponins Chemical class 0.000 description 2
235000017709 saponins Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical class [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
150000005418 4-aminobenzoic acid derivatives Chemical class 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
241000186046 Actinomyces Species 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
241000701242 Adenoviridae Species 0.000 description 1
241000701386 African swine fever virus Species 0.000 description 1
241000272478 Aquila Species 0.000 description 1
241000712892 Arenaviridae Species 0.000 description 1
102100035526 B melanoma antigen 1 Human genes 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
241000335423 Blastomyces Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000589994 Campylobacter sp. Species 0.000 description 1
102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
241001227713 Chiron Species 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
241000193449 Clostridium tetani Species 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241000759568 Corixa Species 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241000186249 Corynebacterium sp. Species 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
201000007336 Cryptococcosis Diseases 0.000 description 1
241000221204 Cryptococcus neoformans Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
241000725619 Dengue virus Species 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
241001115402 Ebolavirus Species 0.000 description 1
241001466953 Echovirus Species 0.000 description 1
241000588914 Enterobacter Species 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
241001495410 Enterococcus sp. Species 0.000 description 1
208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000711950 Filoviridae Species 0.000 description 1
241000710781 Flaviviridae Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
206010061192 Haemorrhagic fever Diseases 0.000 description 1
241000150562 Hantaan orthohantavirus Species 0.000 description 1
241000713858 Harvey murine sarcoma virus Species 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
241000700739 Hepadnaviridae Species 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
241000228404 Histoplasma capsulatum Species 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
101000993094 Homo sapiens Chromogranin-A Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
241000701377 Iridoviridae Species 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
241000589248 Legionella Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
241000589902 Leptospira Species 0.000 description 1
241000186779 Listeria monocytogenes Species 0.000 description 1
108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
241000204795 Muraena helena Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000186367 Mycobacterium avium Species 0.000 description 1
241000187484 Mycobacterium gordonae Species 0.000 description 1
241000186364 Mycobacterium intracellulare Species 0.000 description 1
241000186363 Mycobacterium kansasii Species 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
241000588650 Neisseria meningitidis Species 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000702259 Orbivirus Species 0.000 description 1
241000712464 Orthomyxoviridae Species 0.000 description 1
241000150218 Orthonairovirus Species 0.000 description 1
241000711504 Paramyxoviridae Species 0.000 description 1
241000701945 Parvoviridae Species 0.000 description 1
241000606860 Pasteurella Species 0.000 description 1
241000009328 Perro Species 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
241000224016 Plasmodium Species 0.000 description 1
241000223960 Plasmodium falciparum Species 0.000 description 1
241000223821 Plasmodium malariae Species 0.000 description 1
241001505293 Plasmodium ovale Species 0.000 description 1
241000223810 Plasmodium vivax Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001231 Polysaccharide peptide Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
241000702247 Reoviridae Species 0.000 description 1
241000702263 Reovirus sp. Species 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
241000712907 Retroviridae Species 0.000 description 1
241000711931 Rhabdoviridae Species 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000194049 Streptococcus equinus Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
206010042566 Superinfection Diseases 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
241000710924 Togaviridae Species 0.000 description 1
241000589886 Treponema Species 0.000 description 1
241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
241000710772 Yellow fever virus Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
108700010877 adenoviridae proteins Proteins 0.000 description 1
230000037006 agalactosis Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
244000309743 astrovirus Species 0.000 description 1
229960002756 azacitidine Drugs 0.000 description 1
229940065181 bacillus anthracis Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000010001 cellular homeostasis Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
239000012636 effector Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
230000008995 epigenetic change Effects 0.000 description 1
230000006718 epigenetic regulation Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
238000012226 gene silencing method Methods 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
210000004524 haematopoietic cell Anatomy 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
102000057162 human CHGA Human genes 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000006607 hypermethylation Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000002743 insertional mutagenesis Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
230000001035 methylating effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
230000035772 mutation Effects 0.000 description 1
UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
201000011519 neuroendocrine tumor Diseases 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000009521 phase II clinical trial Methods 0.000 description 1
229940118768 plasmodium malariae Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
108010022457 polysaccharide peptide Proteins 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000001566 pro-viral effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
241000724775 unclassified viruses Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
229940051021 yellow-fever virus Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ES05750379T 2004-05-26 2005-05-26 Composiciones que comprenden agentes desmetilantes como potenciadores de la inmunoterapia para el tratamiento de infecciones cronicas y enfermedades neoplasicas y metodos para tratar las mismas. Expired - Lifetime ES2322172T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US57463804P	2004-05-26	2004-05-26
US574638P		2004-05-26
US58245504P	2004-06-24	2004-06-24
US582455P		2004-06-24
US138171		2005-05-26
US11/138,171 US20050266012A1 (en)	2004-05-26	2005-05-26	Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same

Publications (1)

Publication Number	Publication Date
ES2322172T3 true ES2322172T3 (es)	2009-06-17

Family

ID=35425543

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES05750379T Expired - Lifetime ES2322172T3 (es)	2004-05-26	2005-05-26	Composiciones que comprenden agentes desmetilantes como potenciadores de la inmunoterapia para el tratamiento de infecciones cronicas y enfermedades neoplasicas y metodos para tratar las mismas.

Country Status (6)

Country	Link
US (1)	US20050266012A1 (fr)
EP (1)	EP1748792B1 (fr)
AT (1)	ATE422367T1 (fr)
DE (1)	DE602005012686D1 (fr)
ES (1)	ES2322172T3 (fr)
WO (1)	WO2005115450A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
BR112014004779B1 (pt)	2011-08-30	2022-01-18	Astex Pharmaceuticals, Inc	Formulações de derivados de decitabina, kit e processos relacionados
US11083743B2 (en) *	2013-02-21	2021-08-10	Michele Maio	DNA hypomethylating agents for cancer therapy
RU2019138702A (ru) *	2013-03-01	2020-01-27	Астекс Фармасьютикалз, Инк.	Комбинации лекарственных средств
EP2952182B1 (fr) *	2014-06-04	2022-11-23	Universität Heidelberg	Composés et procédés pour augmenter la réponse immunitaire au virus du papillome
MX2018000016A (es)	2015-07-02	2019-01-31	Otsuka Pharma Co Ltd	Composiciones farmaceuticas liofilizadas.
MX2020001233A (es)	2017-08-03	2020-07-20	Otsuka Pharma Co Ltd	Compuesto farmaceutico y metodos de purificacion del mismo.
US11419928B2 (en)	2017-10-25	2022-08-23	The Johns Hopkins University	Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995028940A1 (fr) *	1994-04-22	1995-11-02	Department Of The Army	Technique d'inhibition du virus de l'immunodeficience humaine
US20030104576A1 (en) *	1994-10-07	2003-06-05	Jonathan W. Nyce	Dna construct, composition, formulations & methods for making the construct & for modulating expression
US20050059682A1 (en) *	2003-09-12	2005-03-17	Supergen, Inc., A Delaware Corporation	Compositions and methods for treatment of cancer

2005
- 2005-05-26 WO PCT/IB2005/001827 patent/WO2005115450A1/fr not_active Ceased
- 2005-05-26 EP EP05750379A patent/EP1748792B1/fr not_active Expired - Lifetime
- 2005-05-26 DE DE602005012686T patent/DE602005012686D1/de not_active Expired - Lifetime
- 2005-05-26 AT AT05750379T patent/ATE422367T1/de not_active IP Right Cessation
- 2005-05-26 US US11/138,171 patent/US20050266012A1/en not_active Abandoned
- 2005-05-26 ES ES05750379T patent/ES2322172T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1748792A1 (fr)	2007-02-07
WO2005115450A1 (fr)	2005-12-08
US20050266012A1 (en)	2005-12-01
ATE422367T1 (de)	2009-02-15
DE602005012686D1 (de)	2009-03-26
EP1748792B1 (fr)	2009-02-11

Publication	Publication Date	Title
JP7765006B2 (ja)	2025-11-06	新生児及び乳幼児におけるワクチン接種
ES2236705T3 (es)	2005-07-16	Complejos proteinicos de estres-peptido en calidad de vacunas profilacticas y terapeuticas contra agentes patogenos intracelulares.
US7655238B2 (en)	2010-02-02	Compositions and methods for enhancing the immunogenicity of antigens
CA2687632C (fr)	2013-01-15	Composition lyophilisee d'antigene
JP4620251B2 (ja)	2011-01-26	Ｃｐｇおよびサポニンアジュバントの組成物並びにその方法
EP1053325B1 (fr)	2006-01-04	Derives antigenes associes aux tumeurs de la famille mage, et sequences d'acides nucleiques codant ces derives, utilises pour la preparaiton de proteines de fusion et de compositions destinees a la vaccination
US7700344B2 (en)	2010-04-20	Compositions and methods for enhancing the immunogenicity of antigens
JP2008222721A6 (ja)	2008-12-11	ワクチン組成物
JP2008222721A (ja)	2008-09-25	ワクチン組成物
US6749856B1 (en)	2004-06-15	Mucosal cytotoxic T lymphocyte responses
JP2005533855A (ja)	2005-11-10	病原性ウイルスからの別のリーディングフレームによりコードされる抗原
BRPI0923341B1 (pt)	2021-04-06	Oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso
KR20060131749A (ko)	2006-12-20	면역원성 조성물
US20180243409A1 (en)	2018-08-30	SYNTHETIC CONJUGATE OF CpG DNA AND T-HELP/CTL PEPTIDE
ES2322172T3 (es)	2009-06-17	Composiciones que comprenden agentes desmetilantes como potenciadores de la inmunoterapia para el tratamiento de infecciones cronicas y enfermedades neoplasicas y metodos para tratar las mismas.
JP6698069B2 (ja)	2020-05-27	免疫賦活活性を有するＣｐＧスペーサーオリゴヌクレオチド含有複合体及びその用途
ES2288627T3 (es)	2008-01-16	Proteina de fusion g de ihnv para estimulacion inmunitaria.
Li et al.	2001	CpG DNA enhances the immune responses elicited by the DNA vaccine against foot-and-mouth disease virus in guinea pigs